Inflammatory Dermatoses

Inflammatory dermatoses such as atopic dermatitis and psoriasis are being explored as adjunctive HBOT targets. Current support is limited to case reports and small cohorts, suggesting possible benefit in selected, treatment-resistant cases through HBOT's anti-inflammatory and tissue-oxygenating effects. This is Level C evidence — preliminary and investigational — not a substitute for established dermatological therapy.